Remove 2002 Remove Data Remove DEA
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. 2002 Jun;42(8):993-1007. 32: United States DEA.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cannabis Trends of 2022

Kind Meds (Cannabis Education Blog)

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2(a), Oct. 21, 1998 , 112 Stat.

Banking 45